Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
Follow-Up Questions
Who is the CEO of Revelation Biosciences Inc?
Mr. James Rolke is the Chief Executive Officer of Revelation Biosciences Inc, joining the firm since 2020.
What is the price performance of REVB stock?
The current price of REVB is $1.3, it has increased 0.77% in the last trading day.
What are the primary business themes or industries for Revelation Biosciences Inc?
Revelation Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Revelation Biosciences Inc market cap?
Revelation Biosciences Inc's current market cap is $3.0M
Is Revelation Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Revelation Biosciences Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
